Correction of anemic syndrome in patients with chronic heart failure with intravenous iron-containing complex

Aim. To evaluate efficacy of intravenous iron (III) hydroxide sucrose complex for anemic sydrome correction in patients with chronic heart failure and anemia.

Methods. 126 patients with chronic heart failure of ischemic etiology of I-IV NYHA functional class were examined, 92 of them were diagnosed with anemia. The average age of patients was 60.6±1.4 years. All patients were randomized into 2 groups. Group 1 included 49 patients with chronic heart failure and anemia who received only basic therapy, including angiotensin converting enzyme inhibitors, β-blockers, diuretics, digoxin, and nitrates. Group 2 included 43 patients with chronic heart failure, anemia and iron deficiency who received combination therapy with intravenous iron (III) hydroxide sucrose complex (Venofer) and basic therapy. In all patients on the treatment levels of hemoglobin, ferritin, transferrin saturation, erythropoietin, N terminal pro brain natriuretic peptide, interleukin 1, interleukin 6, tumor necrosis factor α in plasma, parameters of systolic and diastolic function of the left ventricle myocardium by echocardiography and doppler echocardiography were evaluated dynamically.

Results. In patients with chronic heart failure of I-IV NYHA class and anemia (group 1) on the background of basic therapy, no positive dynamics was registered for levels of hemoglobin, hematocrit, ferritin, transferrin saturation, erythropoietin, N terminal pro brain natriuretic peptide, interleukin 1, interleukin 6, and tumor necrosis factor α. In group 2 during therapy there was a significant increase of the level of hemoglobin, plasma ferritin and transferrin saturation.

Conclusion. Patients with chronic heart failure of I-IV NYHA functional class, anemia, iron deficiency and normoerythropoietinaemia or hypererythropoietinaemia, administration of intravenous iron (III) hydroxide sucrose complex (Venofer) with basic therapy is recommended.